Drug-drug interactions between tyrosine kinase inhibitors and concomitant medications: drug safety in chronic myeloid leukemia treatment.
Frutos Pérez-Surio, Alberto (Universidad de Zaragoza) ; Lozano Ortiz, Roberto ; Martinez Crespo, Alejandro
Resumen: Background: Clinical Pharmacist should be aware of hematologic toxicities from tyrosine kinase inhibitors (TKI) used to treat chronic myelogenous leukemia (CML). Drug-drug interactions (DDI) may be problematic.
Objective: To analyze DDI between TKI and the concomitant medication.
Setting: Retrospective observational study carried in a tertiary hospital of Spain.
Method: A bibliographic search was made on the UpToDate®, Lexicomp® and Micromedex® software platforms to search for evidence on DDI between TKI and the concomitant medication.
Main outcome measure: Number of interactions with respect to sex,to number of concomitant drugs, and to TKI used.
Results: A total of 28 patients were analyzed. 78.6% of patients had medication associated with the TKI. There was a total of 50 significant DDI, out of a total of 128 drugs, so the risk of having interaction in the study population was 39.1%. Regarding the management of the interactions by the hematologist and the acceptance of the pharmaceutical intervention: 10 patients experienced 14 high-level interactions. Of these the doctor knew 50% and had performed intervention in all cases: modify the treatment in 28.6%, consulted with service responsible for treatment in 42.8% and spaced the intake of drugs in 28.6%. It is important to periodically review concomitant medication and to have a strategy to manage interactions. The role of the clinical pharmacist is essential in communication with the patient, assessment of treatments, detecting potential interactions and disseminating information among the multidisciplinary team.
Conclusion: All patients who are prescribed oral antineoplastic drugs are provided patient education materials about TKI, which include possible interactions. Any changes in the patient’s medications prompt a review for DDI.
Idioma: Inglés
Año: 2019
Publicado en: Pharmakeftiki 31, 4 (2019), 192-200
ISSN: 1105-4999
Originalmente disponible en: Texto completo de la revista
Factor impacto SCIMAGO: 0.101 - Pharmacology (Q4) - Pharmaceutical Science (Q4)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Med.Pr.,Sal.Públ.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2023-10-23-12:20:46)
Visitas y descargas
Objective: To analyze DDI between TKI and the concomitant medication.
Setting: Retrospective observational study carried in a tertiary hospital of Spain.
Method: A bibliographic search was made on the UpToDate®, Lexicomp® and Micromedex® software platforms to search for evidence on DDI between TKI and the concomitant medication.
Main outcome measure: Number of interactions with respect to sex,to number of concomitant drugs, and to TKI used.
Results: A total of 28 patients were analyzed. 78.6% of patients had medication associated with the TKI. There was a total of 50 significant DDI, out of a total of 128 drugs, so the risk of having interaction in the study population was 39.1%. Regarding the management of the interactions by the hematologist and the acceptance of the pharmaceutical intervention: 10 patients experienced 14 high-level interactions. Of these the doctor knew 50% and had performed intervention in all cases: modify the treatment in 28.6%, consulted with service responsible for treatment in 42.8% and spaced the intake of drugs in 28.6%. It is important to periodically review concomitant medication and to have a strategy to manage interactions. The role of the clinical pharmacist is essential in communication with the patient, assessment of treatments, detecting potential interactions and disseminating information among the multidisciplinary team.
Conclusion: All patients who are prescribed oral antineoplastic drugs are provided patient education materials about TKI, which include possible interactions. Any changes in the patient’s medications prompt a review for DDI.
Idioma: Inglés
Año: 2019
Publicado en: Pharmakeftiki 31, 4 (2019), 192-200
ISSN: 1105-4999
Originalmente disponible en: Texto completo de la revista
Factor impacto SCIMAGO: 0.101 - Pharmacology (Q4) - Pharmaceutical Science (Q4)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Medic.Prevent.Salud Públ. (Dpto. Microb.Med.Pr.,Sal.Públ.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2023-10-23-12:20:46)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2020-02-21, última modificación el 2023-10-23